Nivalis Therapeutics Inc. (NASDAQ:NVLS) has been given a consensus rating of “Hold” by the seven ratings firms that are covering the company. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.42.

Several research analysts have issued reports on the company. Raymond James Financial Inc. cut Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Stifel Nicolaus cut Nivalis Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $16.00 to $3.25 in a research report on Tuesday. Piper Jaffray Cos. restated a “buy” rating and issued a $16.00 price target on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. HC Wainwright restated a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Finally, Zacks Investment Research upgraded Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target for the company in a research report on Thursday, October 20th.

In related news, EVP David Malcom Rodman sold 5,820 shares of the stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total transaction of $46,327.20. Following the sale, the executive vice president now owns 18,056 shares of the company’s stock, valued at $143,725.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.00% of the company’s stock.

Several hedge funds have recently bought and sold shares of NVLS. AXA raised its stake in shares of Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock worth $2,455,000 after buying an additional 139,652 shares during the last quarter. Opaleye Management Inc. raised its stake in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the last quarter. BVF Inc. IL raised its stake in shares of Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock worth $8,862,000 after buying an additional 379,700 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Nivalis Therapeutics during the second quarter worth about $105,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the last quarter. 79.26% of the stock is currently owned by institutional investors and hedge funds.

Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 59.0416% during mid-day trading on Tuesday, reaching $2.5599. 3,724,921 shares of the company traded hands. Nivalis Therapeutics has a 52-week low of $2.50 and a 52-week high of $9.46. The company’s 50 day moving average is $6.46 and its 200 day moving average is $5.84. The stock’s market capitalization is $39.79 million.

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, equities analysts forecast that Nivalis Therapeutics will post ($2.10) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Nivalis Therapeutics Inc. (NVLS) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this news story can be accessed at http://www.dailypolitical.com/2016/11/29/nivalis-therapeutics-inc-nvls-receives-consensus-rating-of-hold-from-brokerages.html.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.